🇺🇸 FDA
Patent

US 8921316

Stable liquid VEGF antagonist formulations

granted A61KA61K31/4172A61K31/7012

Quick answer

US patent 8921316 (Stable liquid VEGF antagonist formulations) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/4172, A61K31/7012, A61K38/16, A61K38/179